Show simple item record

dc.contributor.authorBELL, ANGUSen
dc.date.accessioned2014-11-25T15:08:44Z
dc.date.available2014-11-25T15:08:44Z
dc.date.issued2013en
dc.date.submitted2013en
dc.identifier.citationBell, A., Antimalarial drug discovery and design in the Era of resistance, Current Pharmaceutical Design, 19, 2, 2013, 264-265en
dc.identifier.otherYen
dc.identifier.urihttp://hdl.handle.net/2262/72193
dc.descriptionPUBLISHEDen
dc.description.abstractThese are interesting times for antimalarial drug research. On the one hand, recent reports from Southeast Asia paint a grim picture of reduced malarial parasite susceptibility to artemisinin combination therapies (ACTs), currently the mainstay of antimalarial treatment in most of the world [1]. History has shown us that the protozoal parasite of malaria (Plasmodium), in particular the most lethal human parasite Plasmodium falciparum, is adept at acquiring resistance to the antimalarial drugs that we have deployed [2]. The fall from grace of former stalwarts such as chloroquine and sulphadoxine + pyrimethamine has in this respect been spectacular: in some regions the therapeutic lifespan of the latter has been as little as 5 years [3].en
dc.format.extent264-265en
dc.language.isoenen
dc.relation.ispartofseriesCurrent Pharmaceutical Designen
dc.relation.ispartofseries19en
dc.relation.ispartofseries2en
dc.rightsYen
dc.subjecteditorialen
dc.subject.lcsheditorialen
dc.titleAntimalarial drug discovery and design in the Era of resistanceen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/abellen
dc.identifier.rssinternalid86816en
dc.identifier.doihttp://dx.doi.org/10.2174/1381612811306020264en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record